Please login to the form below

Not currently logged in
Email:
Password:

Signant Health appoints new chief compliance and security officer

Paul Drake joins with 30 years of experience

Paul Drake

Signant Health, formerly CRF Health and Bracket, has appointed Paul Drake (pictured above) as chief compliance and security officer. 

In this role, Drake will help identify new investments in technology, infrastructure and people to reduce security and privacy risks, ensure accountability around quality and compliance issues and lead certification, audit and other critical efforts.

He has 30 years of experience in security, quality management and data privacy, with 20 of those years in senior life sciences roles.

Signant Health appointed Drake due to his extensive experience in complex integration work, his ability to build internal IT organisations and his successes in complex technology infrastructure and change management.

"Our clients increasingly view data security and privacy as a critical part of their overall quality strategy. While we have made significant steps in these areas, we are dedicated to our customers’ quality expectations around protecting their valuable data and assets,” said Mike Nolte, CEO of Signant Health.

“Paul was chosen due to his extensive background and expertise in these areas, and as someone who can drive effective and innovative solutions to protect data and other assets that our customers entrust to us,” he added.

17th December 2019

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics